Blood coagulation studies in 45 patients with ischemic cerebrovascular disease and 44 patients with venous thromboembolic disease.
Forty-five patients with ischemic cerebrovascular disease (ICD) and 44 with deep venous thrombosis (DVT) and/or pulmonary embolism (PE) have been investigated in a non-active state of the disease with VIIIR:Ag, plasminogen activator before and after stasis, antiplasmin, antithrombin (activity, antigen, activity/antigen ratio) and spontaneous platelet aggregation. Control groups of 20 respectively 80 healthy females and males were used in the study. VIIR:Ag was elevated in the group with deep venous thromboembolic disease compared with the ICD group and a control group. VIIIR:Ag in the ICD group was elevated compared with the control group. Plasminogen activator determined before and after stasis was lowered in the two diseased groups. There was no statistically significant difference in any of the blood coagulation variables between patients on or off coumarol treatment. The patients on courmarol were, however, not reinvestigated when this medication had been withdrawn. Antithrombin levels below the reference interval of the control group of 80 blood donors were found in 11.4% of the patients with DVT/PE, whiel no patient in the ICD group had low antithrombin values.
D000328:Adult; D000991:Antithrombins / Q000032:analysis; D001777:Blood Coagulation; D001780:Blood Coagulation Tests; D002544:Cerebral Infarction / Q000097:blood*; D005169:Factor VIII / Q000032:analysis; D005260:Female; D006801:Humans; D002546:Ischemic Attack, Transient / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010960:Plasminogen Activators / Q000032:analysis; D010974:Platelet Aggregation; D011655:Pulmonary Embolism / Q000097:blood*; D013924:Thrombophlebitis / Q000097:blood*; D000979:alpha-2-Antiplasmin / Q000032:analysis
D000991:Antithrombins; D000979:alpha-2-Antiplasmin; D005169:Factor VIII; D010960:Plasminogen Activators